FN2 Earnings Intelligence
BridgeBio Pharma, Inc. income statement (quarterly)
BridgeBio Pharma, Inc. (BBIO) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $540.6 | $749 | $643 | $879.9 | $677.9 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $116.6 | $110.6 | $120.7 | $194.5 | $243.7 | $269 | $314.8 |
| % Growth | - | - | - | - | - | 122.9% | - |
| Gross Profit | $114 | $106.9 | $114.1 | $184.6 | $228.6 | - | - |
| % Margin | 97.7% | 96.7% | 94.6% | 94.9% | 93.8% | - | - |
| EBITDA | -$103.1 | - | - | -$104.8 | - | - | - |
| % Margin | -88.4% | - | - | -53.9% | - | - | - |
| Net Income | -$169.6 | -$183.8 | -$184.9 | -$166.6 | -$155.9 | - | - |
| % Margin | -145.4% | -166.2% | -153.2% | -85.6% | -64.0% | - | - |
| Diluted EPS | -$0.88 | -$0.95 | -$0.95 | -$0.84 | -$0.78 | -$0.61 | -$0.43 |
| % Growth | - | - | - | - | - | 35.6% | - |
| Operating Cash Flow | -$199.2 | - | - | -$197.3 | - | - | - |
| CapEx | $0 | - | - | $0.1 | - | - | - |
| Free Cash Flow | -$199.2 | - | - | -$197.3 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $116.6 | $110.6 | $120.7 | $194.5 | $243.7 | $269 | $314.8 |
| Gross Profit | $114 | $106.9 | $114.1 | $184.6 | $228.6 | - | - |
| EBITDA | -$103.1 | - | - | -$104.8 | - | - | - |
| Net Income | -$169.6 | -$183.8 | -$184.9 | -$166.6 | -$155.9 | - | - |
| Diluted EPS | -$0.88 | -$0.95 | -$0.95 | -$0.84 | -$0.78 | -$0.61 | -$0.43 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $540.6 | $749 | $643 | $879.9 | $677.9 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $0 | $0 | $2,007.3 | $2,652.9 | $2,652.9 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$199.2 | - | - | -$197.3 | - |
| Capital Expenditure | $0 | - | - | $0.1 | - |
| Free Cash Flow | -$199.2 | - | - | -$197.3 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 97.7% | 96.7% | 94.6% | 94.9% | 93.8% |
| EBITDA Margin | -88.4% | - | - | -53.9% | - |
| Net Margin | -145.4% | -166.2% | -153.2% | -85.6% | -64.0% |
| FCF Margin | -170.8% | - | - | -101.5% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the BBIO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.